MX2022006803A - Formulaciones oftalmicas para el tratamiento de la presbicia. - Google Patents

Formulaciones oftalmicas para el tratamiento de la presbicia.

Info

Publication number
MX2022006803A
MX2022006803A MX2022006803A MX2022006803A MX2022006803A MX 2022006803 A MX2022006803 A MX 2022006803A MX 2022006803 A MX2022006803 A MX 2022006803A MX 2022006803 A MX2022006803 A MX 2022006803A MX 2022006803 A MX2022006803 A MX 2022006803A
Authority
MX
Mexico
Prior art keywords
pharmaceutical formulation
presbyopia
treatment
ophthalmic formulations
disclosure relates
Prior art date
Application number
MX2022006803A
Other languages
English (en)
Inventor
Paul Karpecki
Sharron Acosta
Joseph Terrence Kavanagh
Melissa Kleman
Arthur A Medina Jr
Original Assignee
Restore Vision Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Restore Vision Llc filed Critical Restore Vision Llc
Publication of MX2022006803A publication Critical patent/MX2022006803A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La divulgación se refiere a una formulación farmacéutica que comprende una composición de nanopartículas que proporciona un suministro controlado de uno o una combinación de agentes terapéuticos. Además, la divulgación se refiere a una formulación farmacéutica que comprende una pluralidad de nanopartículas recubiertas, en donde la nanopartícula recubierta comprende una partícula central que comprende un agente farmacéutico sólido o una sal del mismo. La divulgación se refiere además a los métodos de tratamiento de una o más afecciones o enfermedades oftálmicas que comprenden la administración de una cantidad terapéuticamente eficaz de una formulación farmacéutica divulgada.
MX2022006803A 2019-12-04 2020-12-04 Formulaciones oftalmicas para el tratamiento de la presbicia. MX2022006803A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962943400P 2019-12-04 2019-12-04
US202063000652P 2020-03-27 2020-03-27
PCT/US2020/063311 WO2021113637A1 (en) 2019-12-04 2020-12-04 Ophthalmic formulations for the treatment of presbyopia

Publications (1)

Publication Number Publication Date
MX2022006803A true MX2022006803A (es) 2022-09-19

Family

ID=76222698

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006803A MX2022006803A (es) 2019-12-04 2020-12-04 Formulaciones oftalmicas para el tratamiento de la presbicia.

Country Status (4)

Country Link
US (1) US20220071994A1 (es)
EP (1) EP4069220A4 (es)
MX (1) MX2022006803A (es)
WO (1) WO2021113637A1 (es)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1655021B1 (en) * 2004-11-09 2008-10-29 Novagali Pharma SA Oil-in-water type emulsion with low concentration of cationic agent and positive zeta potential
CA2672973C (en) * 2006-12-21 2016-03-08 Novagali Pharma Sa Process for manufacturing ophthalmic oil-in-water emulsions
WO2010123547A1 (en) * 2009-04-21 2010-10-28 Albert Einstein College Of Medicine Of Yeshiva University Versatile nanoparticulate biomaterial for controlled delivery and/or containment of therapeutic and diagnostic material
US8299079B2 (en) * 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
US8987270B2 (en) * 2009-07-27 2015-03-24 Eye Therapies Llc Formulations of selective alpha-2 agonists and methods of use thereof
NZ728721A (en) * 2012-05-03 2018-05-25 Kala Pharmaceuticals Inc Pharmaceutical nanoparticles showing improved mucosal transport
WO2013169538A1 (en) * 2012-05-08 2013-11-14 Albert Einstein College Of Medicine Of Yeshiva University Nanoparticle delivery vehicle for s-nitroso-n-acetyl cysteine and uses thereof
US20190038609A1 (en) * 2013-08-28 2019-02-07 Presbyopia Therapies, LLC Compositions and methods for the treatment of presbyopia
WO2015195458A1 (en) * 2014-06-17 2015-12-23 Albert Einstein College Of Medicine, Inc. Therapeutic nanoparticles and methods thereof
CA2968926C (en) * 2014-11-25 2023-01-17 Izhar Halahmi Compositions and methods for delivering a bio-active agent or bio-active agents
US20180256509A1 (en) * 2014-12-10 2018-09-13 Albert Einstein College Of Medicine, Inc. Nanoparticle Compositions and Methods Thereof to Restore Vascular Integrity
MX2020004666A (es) * 2017-11-17 2022-01-26 Cellix Bio Private Ltd Compuestos de pilocarpina con ácido lipoico para el tratamiento de trastornos oculares.

Also Published As

Publication number Publication date
EP4069220A1 (en) 2022-10-12
US20220071994A1 (en) 2022-03-10
EP4069220A4 (en) 2024-04-24
WO2021113637A1 (en) 2021-06-10

Similar Documents

Publication Publication Date Title
NZ604029A (en) Methods of treating bladder cancer
WO2011106702A3 (en) Sustained delivery of therapeutic agents to an eye compartment
MX369728B (es) Métodos para mejorar suministro de fármacos y efectividad de agentes terapéuticos.
PH12014501560A1 (en) Carbamate compounds and of making and using same
FI3157527T3 (fi) Ezh2-inhibiittoreita lymfoman hoitoon
MX2021005651A (es) Combinacion farmaceutica para el tratamiento contra el cancer.
EA033113B1 (ru) Способы лечения аутоиммунных, респираторных и воспалительных расстройств ингаляцией n-оксида рофлумиласта
MX2014002459A (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos.
MX2014002460A (es) Inhibidores de la quinurenina-3-monooxigenasa, sus composiciones farmaceuticas y metodos para uso.
IN2014MN00139A (es)
EA033448B1 (ru) Композиция орлистата и акарбозы с модифицированным высвобождением для лечения ожирения и связанных метаболических нарушений
CA2986891C (en) Compositions for use in treating parkinson's disease and related disorders
MX2017006938A (es) Terapia de combinacion para el tratamiento de cancer.
WO2014160216A3 (en) Dual targeting anticancer agents
PH12021550047A1 (en) USE OF sGC STIMULATORS FOR THE TREATMENT OF MITOCHONDRIAL DISORDERS
WO2019195761A3 (en) Pharmacological agents for treating ocular diseases
AU2018282104A1 (en) Use of vibegron to treat overactive bladder
SG178942A1 (en) Method of treatment of neurodegenerative or neuro-muscular degenerative diseases and therapeutic agent to treat the same
MX2020006309A (es) Fórmulaciones de parasiticida de isoxazolina y métodos para el tratamiento de la blefaritis.
MX2021011230A (es) Administracion subcutanea de nanoparticulas que comprenden un inhibidor del objetivo de la rapamicina en mamiferos (mtor) y albumina para tratamiento de enfermedades.
CL2020001426A1 (es) Composición tópica oftálmica que comprende ácido dobesilico para tratar enfermedades del segmento posterior del ojo.
MX2022006803A (es) Formulaciones oftalmicas para el tratamiento de la presbicia.
AU2017261303A1 (en) Ophthalmic compositions
IL250852B (en) Periodontal preparation
MX2021009082A (es) Compuestos quimicos.